Not only randomized controlled trials, but also case series should be considered in systematic reviews of rapidly developing technologies
Accepted 5 December 2008. published online 06 April 2009.
Abstract
Objective
Case series can influence clinical practice but are often omitted from systematic reviews. We evaluated the contribution of case series to a systematic review of radiofrequency catheter ablation (RFCA) for treatment of atrial fibrillation (AF).
Study Design and Setting
Analysis of the results of a systematic review based on a search of 25 electronic databases and Internet sources.
Results
We included eight controlled trials and 53 case series. Case series provided most patients longest follow-up and data on adverse events and complications. Rates of freedom from arrhythmia were comparable between case series, RFCA arms of controlled trials, and a survey of RFCA centers.
Conclusion
In the case of RFCA for AF, the case series make a useful contribution to the systematic review. Inclusion of case series can increase the evidence base and strengthen the credibility of a review of an emerging health technology. These advantages must be balanced against the risk of bias associated with the lack of a control group, potential publication bias, overrepresentation of results from specialist centers, and overlap of patients across series. Specification in the review protocol of inclusion criteria for outcomes and quality criteria is recommended to make optimum use of case series.
Centre for Reviews and Dissemination, University of York, York, UK
Corresponding author. Centre for Reviews and Dissemination, University of York, Heslington, York YO10 5DD, UK. Tel.: +44-0-1904-321097; fax: +44-0-1904-321041.
ABSTRACT